News Releases

 
News Releases
  Date Title and Summary View
Oct 18, 2016
-- CCX872 reduced hepatic inflammation, steatosis, and scarring in models of non-alcoholic steatohepatitis (NASH) -- -- Findings reported at the American College of Gastroenterology (ACG) 2016 Annual Meeting -- MOUNTAIN VIEW, Calif., Oct. 18, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced the presentation of da...
Oct 17, 2016
MOUNTAIN VIEW, Calif., Oct. 17, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that positive data from an ongoing Phase II proof-of-concept study of CCX168 for the treatment of Atypical Hemolytic Uremic Syndrome (aHUS) will be presented at the American Society of Nephrology (ASN) Kidney Week 2016 Annual Meeting. CCX16...
Sep 1, 2016
MOUNTAIN VIEW, Calif., Sept. 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI) today announced initial 12 week overall response rate (ORR) results from an ongoing open label, single arm Phase Ib clinical trial with CCX872 in patients with advanced pancreatic cancer. CCX872 is a selective inhibitor of the chemokine receptor known as C...
Aug 25, 2016
MOUNTAIN VIEW, Calif., Aug. 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at th...
Aug 8, 2016
-- Successfully Completed Phase II ANCA-Associated Vasculitis (AAV) Development Program of Complement 5a Receptor Inhibitor CCX168 -- -- Awarded EMA PRIority MEdicines (PRIME) Designation for Accelerated Assessment of CCX168 in AAV, as well as FDA Orphan Products Development Grant for CCX168 for Treatment of AAV -- -- Plan to Report Initial D...
Aug 1, 2016
MOUNTAIN VIEW, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the Company's second quarter 2016 financial results will be released after market c...
Jun 29, 2016
MOUNTAIN VIEW, Calif., June 29, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at th...
Jun 16, 2016
-- Safety study objective achieved: CCX168 shown to be well tolerated in patients with ANCA-associated vasculitis when added to current standard of care regimen -- -- Initiation of Phase III development program with CCX168 in ANCA-associated vasculitis planned by the end of 2016 -- MOUNTAIN VIEW, Calif., June 16, 2016 (GLOBE NEWSWIRE) -- C...
Jun 1, 2016
MOUNTAIN VIEW, Calif., June 01, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced it received PRIority MEdicines (PRIME) designation from the European Medicines Agency (...
May 25, 2016
MOUNTAIN VIEW, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company developing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer, today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the...
Page: FirstPrevious
2
... NextLast
= add release to Briefcase